Morgan Stanley analyst Michael Cyprys lowered the firm’s price target on CME Group (CME) to $353 from $362 and keeps an Overweight rating on the shares. The firm sees CME “extending its futures exchange moat and paving way for new growth vectors that are not yet in the price,” but is modestly lowering its 2027 EPS estimate by 2.5% to reflect a softer rate per contract outlook, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CME: